Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chan

Showing results (151-160 of 170) with videos related to

Pageof 17
Sort By:
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Epilepsia|April 12, 2024
Hippocampal sclerosis and temporal lobe epilepsy following febrile status epilepticus: The FEBSTAT studyDarrell V Lewis, James Voyvodic, Shlomo Shinnar, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.
Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
JHEP Reports : Innovation in Hepatology|July 8, 2024
Dual-tracer PET/CT in the management of hepatocellular carcinomaKeith Wan Hang Chiu, Chi Leung Chiang, Kenneth Sik Kwan Chan, et al.
European Journal of Neurology|March 25, 2026
Risdiplam Impact in Treatment Naïve and Non-Naïve Pediatric and Adult Patients With Spinal Muscular AtrophyPak On Patrick Yee, Hayley Hoi Ning Ip, Michael Kwan Leung Yu, et al.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
Pageof 17

Showing results (151-160 of 170) with videos related to

Sort By:
Pageof 17
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Epilepsia|April 12, 2024
Hippocampal sclerosis and temporal lobe epilepsy following febrile status epilepticus: The FEBSTAT studyDarrell V Lewis, James Voyvodic, Shlomo Shinnar, et al.
Nature Communications|May 31, 2020
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancerNeha Chopra, Holly Tovey, Alex Pearson, et al.
The Lancet. Oncology|October 8, 2013
Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 studyAhmad Awada, Agustin A Garcia, Stephen Chan, et al.
Molecular Cancer Therapeutics|October 16, 2004
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxelVirginie Durbecq, Marianne Paesmans, Fatima Cardoso, et al.
The Lancet. Oncology|December 24, 2013
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trialHelena M Earl, Anne-Laure Vallier, Louise Hiller, et al.
JHEP Reports : Innovation in Hepatology|July 8, 2024
Dual-tracer PET/CT in the management of hepatocellular carcinomaKeith Wan Hang Chiu, Chi Leung Chiang, Kenneth Sik Kwan Chan, et al.
European Journal of Neurology|March 25, 2026
Risdiplam Impact in Treatment Naïve and Non-Naïve Pediatric and Adult Patients With Spinal Muscular AtrophyPak On Patrick Yee, Hayley Hoi Ning Ip, Michael Kwan Leung Yu, et al.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
Pageof 17